BioSerenTach Inc –{•¶‚ÖƒWƒƒƒ“ƒv
BioSerenTach has the following innovative three DDS technologies.

The possible clients are pharmaceutical companies.

BioSerenTach performs pre-clinical study and clinical phase I study with the clients.


Dissolving Micropile (DM) chip

DM is a novel transdermal DDS. DM is composed of water-soluble thread-forming polymer and drug that exists as solid dispersion or suspension. 100-300 micropiles are formed on a chip, 1.0 c‡u, where the length is 500ƒÊm and the diameter of the base is 300ƒÊm. As polymer, chondroitin sulfate, sodium hyarulonate, dextran and albumin are used. Drug is localized at the acral portion of micropiles. After insertion into the skin by pressing with a finger, polymer dissolves in the epiderm and drug is immediately released and absorbed into the systemic circulation. As a drug, vaccine antigen, insulin, erythropoietin (EPO), interferon (IFN) and growth hormone (GH) are recommended.
Sophisticated skin vaccine DM was innovated in 2017.

see details of our technologies






Gastrointestinal mucoadhesive patch system
(GI-MAPSTM)


GI-MAPS is especially recommended to
glycoprotein drugs like EPO and G-CSF and peptide like semaglutide, GLP-1 receptor agonist.
New tablet type GI-MAPS was developed in 2017. New GI-MAPS gives higher absorption rate of drug and has low production cost.

see details of our technologies


Three-layered microcapsules

For a long-term sustained-release injection preparation of leuprolide acetate, insulin, calcitonin, IFN, EPO, G-CS and GH etc
Microcapsules composed of three layers, (1) surface layer, (2) drug-carrying layer and (3) basement, have been developed. The surface layer has a function of controlling the release rate of drug. By selecting the compostion of the surface layer, long-term sustained-release injection preparation, for example one month, is prepared. Feasibility study was performed with EPO, leuprolide acetate and low molecular weight heparin (LMWH) with poly-ƒÃ-caprolactone and sustained-release charactersitics for about 10 days was ascertained in rat experiments. BioSerenTach is now developing a machine to produce three-layered microcapsules.



@

Copyright BioSerenTach Inc, 2019